OnKure Therapeutics (OKUR)
Develops mutation-selective PI3Kα medicines for cancer and vascular anomalies.
Something off on this page? Send us feedback.
Develops mutation-selective PI3Kα small molecules for cancer and vascular anomalies. Its pipeline centers on OKI-345 for breast cancer and OKI-355 for vascular anomalies; it has no approved products or product-sales revenue.
Develops mutation-selective small molecules for PI3Kα-driven cancers and vascular anomalies. Its named next-generation candidates are OKI-345 for breast cancer and OKI-355 for vascular anomalies, while OKI-219 is no longer planned for independent development.
Structure-based and computational-chemistry-driven design supports small-molecule programs that preferentially target disease-driving mutations while sparing wild-type PI3Kα. The company operates as a clinical-stage biopharmaceutical company, based in Boulder, Colorado, with no approved products or product-sales revenue.
The programs require additional capital before meaningful product revenue can be generated. Clinical progress, regulatory clearance, and continued financing determine whether its programs can reach commercialization.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Reiterate | Rating: —Target: $35 | Target: $14 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $176.4M · Total debt $926.0K · Total assets $179.4M · Shareholders' equity $172.1M
- Revenue
- $0
- Operating income
- −$16.9M
- Net income
- −$15.3M
No dividends on record.
| Institutions | 86.25% | 34.93M shares | |
|---|---|---|---|
| 76 holders · as of Jun 30, 2026 | |||
| Insiders | 8.28% | 3.35M shares | |
| 6 holders · as of Jun 24, 2026 | |||
| Other | 5.47% | 2.21M shares | |
| remainder | |||
40.50M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
1 position filed across a stock split leaves its adjustment unstated and stays out of the bar.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 9.87% | 4.00M | as of Jun 30, 2026 |
BVF Inc/ILInstitution | 7.99% | 3.24M | as of Jun 30, 2026 |
Bioventures L.p. Acorn1Insider10 percent owner | 7.01% | 2.84M | filed May 19, 2025 |
Acorn Capital Advisors, LLCInstitution | 7.01% | 2.84M | as of Jun 30, 2026 |
Stepstone Group LPInstitution | 6.57% | 2.66M | as of Jun 30, 2026 |
- Bioventures L.p. Acorn reports a block also reported by Trails Edge Capital Partners, LP; it is counted once, under Trails Edge Capital Partners, LP.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 22, 2026 | Jason A. Leverone | officer: Chief Financial Officer | −303 | $4.40 |
| Jun 22, 2026 | Nicholas A. Saccomano | director, officer: President and CEO | −86 | $4.40 |
| Mar 23, 2026 | Jason A. Leverone | officer: Chief Financial Officer | −301 | $4.16 |
| Mar 23, 2026 | Nicholas A. Saccomano | director, officer: President and CEO | −86 | $4.16 |
| Dec 22, 2025 | Jason A. Leverone | officer: Chief Financial Officer | −302 | $2.97 |
- Relay Therapeutics
Pan-mutant PI3Kα programs in breast cancer and vascular anomalies
- Novartis (ADR)
PI3Kα therapy in PIK3CA-mutated breast cancer and PROS
- AstraZeneca (ADR)
AKT therapy for PIK3CA/AKT1/PTEN-altered breast cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OnKure Therapeutics | $2.94 | −5.16% | $125.5M | — | — | — | — |
| Relay Therapeutics | $17.52 | −9.46% | $4.24B | — | — | 409.7 | −48.3% |
| Novartis (ADR) | $142.21 | +0.66% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| AstraZeneca (ADR) | $164.51 | −2.30% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Median | 23.3 | 15.3 | 4.8 | +0.9% |